Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.48 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145739 | 0.87 | CHRM1 (0.53) | GRM1SLC6A7GPR119CHRM1CHRM2 | |
| SCHEMBL16236002 | 0.85 | GRM1 (0.64) | GRM1SLC6A7CHRM4 | |
| SCHEMBL26087401 | 0.83 | CHRM2 (0.56) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL26086799 | 0.83 | CHRM2 (0.56) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL26087065 | 0.83 | CHRM4 (0.55) | GRM1CHRM1CHRM2PIK3CDCHRM4 | |
| SCHEMBL27233857 | 0.83 | CHRM2 (0.56) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL1448170 | 0.81 | GPR119 (0.65) | GRM1SLC6A7GPR119 | |
| SCHEMBL12740835 | 0.81 | GPR119 (0.65) | GRM1SLC6A7GPR119 | |
| SCHEMBL1448169 | 0.81 | GPR119 (0.65) | GRM1SLC6A7GPR119 | |
| SCHEMBL21551278 | 0.81 | GPR119 (0.59) | SLC6A7GPR119CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | GRM1 4726/4885SLC6A7 1091/4885GPR119 2318/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | GRM1 4726/4885SLC6A7 1091/4885GPR119 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.